Genetically Engineered and Implantable Mouse Brain Tumor Models: Characterization by Immunohistochemistry and Flow Cytometry
Current Protocols · 2025
DOI: 10.1002/cpz1.70080 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Protocols, 2025. Verfasst von Apoorva Mirji und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Michigan Medicine, University of Michigan Medical School, Ann Arbor, Michigan. Hauptthemen laut MEDLINE: Brain Neoplasms, Flow Cytometry, Disease Models, Animal, Immunohistochemistry. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NIBIB NIH HHS.
Abstract (Originalsprache)
Gliomas are aggressive tumors with a poor prognosis. The protocols presented here outline the methods used to study tumor progression, the tumor microenvironment (TME), and the effects of experimental treatments. The Sleeping Beauty (SB) transposase system induces tumors de novo to generate mouse models that recapitulate human gliomas. Plasmids are constructed with oncogenic drivers and other genetic alterations of interest. which are recognized by their unique position in between inverted/direct repeat (IR/DR) sequences. Luciferase enzyme is used to monitor the uptake of the plasmid, tumor growth, and response to experimental therapies. The genes of interest are tracked using fluorescent markers. Tumors will arise in immunocompetent hosts, which provides a relevant preclinical platform for analysis of tumor initiation, progression, survival, immune microenvironment, and histopathological features. Once the tumor grows within the desired brain location, it can be harvested to generate cell cultures of neurospheres for future experimentation. The benefit of implantable models generated from SB tumors is that they provide specific anatomical and genetic context, in which specific genetic characteristics can be tracked, as they are co‐expressed with fluorescent markers. Post glioma cell implantation, additional analysis of the TME and tumor growth can be performed through immunohistochemistry (IHC) and flow cytometry. © 2025 Wiley Periodicals LLC. Basic Protocol 1 : Creation of mouse glioma models by Sleeping‐Beauty‐mediated transposition Basic Protocol 2 : Generation of orthotopic implantable brain tumors and neurospheres Basic Protocol 3 : Hematoxylin and eosin staining of glioma tissue samples Basic Protocol 4 : Immunohistochemistry of glioma tissue samples Basic Protocol 5 : Flow cytometry for immune cell analysis of the tumor microenvironment
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Michigan Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
- Department of Cell and Developmental Biology, Michigan Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
- Rogel Cancer Center, Michigan Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
ORCID-Profile: Maria G Castro
Förderung
- NINDS NIH HHS
- NIBIB NIH HHS
Zitieren
APA
Mirji, A., Singh, G., Mujeeb, A. A., McClellan, B. L., Li, Y., Perez, M., & Castro, M. G. (2025). Genetically Engineered and Implantable Mouse Brain Tumor Models: Characterization by Immunohistochemistry and Flow Cytometry. Current Protocols. https://doi.org/10.1002/cpz1.70080
Vancouver
Mirji A, Singh G, Mujeeb AA, McClellan BL, Li Y, Perez M, et al. Genetically Engineered and Implantable Mouse Brain Tumor Models: Characterization by Immunohistochemistry and Flow Cytometry. Current Protocols. 2025. doi:10.1002/cpz1.70080
BibTeX
@article{Mirji2025,
author = {Mirji, Apoorva and Singh, Gurveer and Mujeeb, Anzar A and McClellan, Brandon L and Li, YingXiang and Perez, Makayla and Castro, Maria G},
title = {Genetically Engineered and Implantable Mouse Brain Tumor Models: Characterization by Immunohistochemistry and Flow Cytometry},
journal = {Current Protocols},
year = {2025},
doi = {10.1002/cpz1.70080}
}
EUVIMED